Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that ...
Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< ...
Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s Eylea in a phase 3 study, teeing up filings for ...
Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to Q20W. SAN FRANCISCO ...
Japan MHLW grants marketing authorization to Bayer’s Eylea 8 mg to treat patients with macular edema following RVO: Berlin Tuesday, March 24, 2026, 13:00 Hrs [IST] The Ministry ...
Meta-analysis shows obstructive sleep apnea is linked to a 45% increased risk for age-related macular degeneration.
If you have dry age-related macular degeneration, your central vision may end up blurry, distorted or dim.
Chugai Pharma files regulatory application with Japanese MHLW for medical device component of the Port Delivery Platform with ranibizumab: Tokyo Friday, March 20, 2026, 11:00 Hrs ...
Long-term nitrogen dioxide exposure significantly increases cataract surgery risk for urban residents; black carbon correlates with nAMD risk.
A widely used diabetes medicine may offer an unexpected benefit for eye health, according to a new study. Researchers have ...
Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that three scientific abstracts highlighting its commercial products VEVYE® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results